Aclaris Therapeutics reports positive Phase 1b data for ATI‑052 in atopic dermatitis and asthma
Aclaris Therapeutics announced that its investigational antibody ATI‑052 produced statistically significant improvements in a Phase 1b trial for severe atopic dermatitis and a separate Phase 1b trial for mild‑to‑moderate asthma. The atopic dermatitis study showed a 45% placebo‑adjusted gain in EASI score and 43% itch relief, while the asthma study reported a 59% reduction in FeNO and a 200 ml increase in FEV1. The company said the safety profile was favorable and said it will prioritize a Phase 2b trial in eosinophilic esophagitis in early 2027.
Why it matters
The positive proof‑of‑concept data could advance ATI‑052 toward later‑stage trials and broaden Aclaris’ pipeline, while the stock fell 9.5% in pre‑market trading after the announcement, reflecting market reaction to the early‑stage results.
Key facts
- 1The atopic dermatitis trial enrolled 14 patients, with a 3:1 randomization to ATI‑052 versus placebo. rttnews.com
- 2Patients received five weekly doses of 480 mg ATI‑052 over four weeks. rttnews.com
- 3ATI‑052 achieved a 45% placebo‑adjusted improvement in the EASI score at Day 57. rttnews.com
- 4Itch relief was 43% placebo‑adjusted at Day 57. rttnews.com
- 5The asthma trial enrolled 16 patients with elevated baseline FeNO. rttnews.com
- 6A single 480 mg dose produced a 59% mean reduction in FeNO by Day 15 versus 15% for placebo. rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.